-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Ophthalmic pharmaceutical clinical trials: design considerations
Paul Varner
Clinical Trail Perspective: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Eratum: Clin Invest (2014) 4(2), 227-234.
Erratum: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment ationale and clinical trials.
Stanislas Pol
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of ALK-driven malignancies
Luca Mologni & Carlo Gambacorti-Passerini
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design of clinical trials for erectile dysfunction
Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for erectile dysfunction
Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for erectile dysfunction
Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for erectile dysfunction
Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for erectile dysfunction
Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for erectile dysfunction
Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for erectile dysfunction
Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for erectile dysfunction
Naif Alhathal, Talal Al-Qaoud,Serge Carrier
Clinical Trail Methodology: Clinical Investigation
-
Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino
Review Article: Clinical Investigation
-
Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino
Review Article: Clinical Investigation
-
Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino
Review Article: Clinical Investigation
-
Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino
Review Article: Clinical Investigation
-
Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino
Review Article: Clinical Investigation
-
Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino
Review Article: Clinical Investigation
-
Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino
Review Article: Clinical Investigation
-
Diffuse large B-cell lymphoma: update on therapy and prognosis
Manuel Gotti, Valeria Fiaccadori, Ercole Brusamolino
Review Article: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation
-
Challenges and prospects for stem cell-based therapy in Type 1 diabetes
News and Views: Clinical Investigation